Adding immune checkpoint inhibitors to chemotherapy in elderly cancer patients: Beneficial for many but not all?

These findings suggest that while the addition of ICIs can enhance survival outcomes in a subset of elderly cancer patients, its efficacy is highly contingent upon the cancer type and the specific patient's health profile.